Filing Flows › Comparisons › YARW vs RNAC
Yarrow Bioscience vs Cartesian Therapeutics: YARW and RNAC compared
Yarrow Bioscience is the larger company: $97K of revenue in its latest quarter (Q2 2026) against $78K for Cartesian Therapeutics (Q1 2026). Yarrow Bioscience is growing faster (+41% against -93% a year earlier).
Where the money goes: YARW and RNAC
Yarrow Bioscience (YARW) · Q2 2026
Yarrow Bioscience, Q2 2026: revenue $97K (+41% year over year), net loss $3.0M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
Cartesian Therapeutics (RNAC) · Q1 2026
Cartesian Therapeutics, Q1 2026: revenue $78K (-93% year over year), net loss $39.2M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.
| Yarrow Bioscience (YARW) | Cartesian Therapeutics (RNAC) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 2026 |
| Revenue | $97K | $78K |
| Revenue growth, Y/Y | +41% | -93% |
| Operating margin | n/m | n/m |
| Net earnings | −$3.0M | −$39.2M |
| Operating cash flow | −$2.0M | −$22.1M |
Questions
Which is bigger, Yarrow Bioscience or Cartesian Therapeutics?
Yarrow Bioscience is the larger company: $97K of revenue in its latest quarter (Q2 2026) against $78K for Cartesian Therapeutics (Q1 2026).
Is Yarrow Bioscience or Cartesian Therapeutics growing faster?
Yarrow Bioscience is growing faster (+41% against -93% a year earlier).
More: Yarrow Bioscience earnings · how Yarrow Bioscience makes money · Cartesian Therapeutics earnings · how Cartesian Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Apr 30, 2026). Fiscal quarters can end on different dates. Not investment advice.